Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Xiuzhen TONG"'
Publikováno v:
Heliyon, Vol 8, Iss 9, Pp e10610- (2022)
Objective: We tried to identify novel molecular subtypes of acute myeloid leukemia (AML) associated with histone methylation and established a relevant scoring system to predict treatment response and prognosis of AML. Methods: Gene expression data a
Externí odkaz:
https://doaj.org/article/903b1fb5ba894ca49e7ad3a97476bc68
Autor:
Fengqi Liu, Hehua Wang, Junru Liu, Zhenhai Zhou, Dong Zheng, Beihui Huang, Chang Su, Waiyi Zou, Duorong Xu, Xiuzhen Tong, Juan Li
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 5108-5115 (2019)
Abstract In acute myeloid leukemia (AML), myelodysplasia‐related changes contribute to a poor prognosis. This retrospective, propensity score‐matched study analyzed 108 newly diagnosed AML patients with features of myelodysplasia syndrome (MDS) (
Externí odkaz:
https://doaj.org/article/b8d347e9126f4840bdba0d415c4691f8
Publikováno v:
Dermatologica Sinica, Vol 31, Iss 2, Pp 98-101 (2013)
Mantel cell lymphoma is one of the small B-cell non-Hodgkin's lymphomas and usually involves lymph nodes, bone marrow, spleen, liver, gastrointestinal tract, and Waldeyer's ring, but rarely skin and orbit. A 53-year-old man presented skin nodules and
Externí odkaz:
https://doaj.org/article/ec9fa286280e4fb3937a235590a93e91
Autor:
Meifeng Zhou, Xiuzhen Tong
Publikováno v:
Diagnostic Pathology, Vol 13, Iss 1, Pp 1-1 (2018)
This article [1] is retracted at request of the Editor.
Externí odkaz:
https://doaj.org/article/2975b37ca52d408abc06c26c1cda3acc
Publikováno v:
Anti-cancer agents in medicinal chemistry. 22(12)
Background: SH3-domain-binding glutamic acid-rich protein-like protein (SH3BGRL) is downregulated in acute myeloid leukemia (AML). Clinically, DNA demethylating drug decitabine (DAC) combined with traditional chemotherapies reveals better efficacy on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89916467b4b2983d4c9f8a41fa032832
https://pubmed.ncbi.nlm.nih.gov/34963436
https://pubmed.ncbi.nlm.nih.gov/34963436
Background: Acute myeloid leukemia (AML) is a type of heterogeneous disease with varied prognosis, but current classification methods for AML do not play an ideal role in guiding the therapy. Emerging studies shown alteration of histone methylation i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff7256a71b4c13a35ca7bcb6b2ece44f
https://doi.org/10.21203/rs.3.rs-629632/v1
https://doi.org/10.21203/rs.3.rs-629632/v1
Publikováno v:
Neoplasma. 68(4)
Phosphatase of regenerating liver-3 (PRL-3) is recognized as a novel independent crucial driver for AML progression. Thus, the specific inhibitor of PRL-3 would be a potential therapeutic agent to AML in clinics, but there are not enough preclinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa8e41ec8792180bba5c4a1570125196
https://pubmed.ncbi.nlm.nih.gov/34348467
https://pubmed.ncbi.nlm.nih.gov/34348467
Phosphatase of regenerating liver-3 (PRL-3) is recognized as a novel independent crucial driver for AML progression. Thus, the specific inhibitor of PRL-3 would be a potential therapeutic agent to AML in clinic, but there is no such preclinical appli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::377c9a3d68ea6b415d6028eb8bf8e381
https://doi.org/10.21203/rs.3.rs-191026/v1
https://doi.org/10.21203/rs.3.rs-191026/v1
Autor:
Xiaozhe Li, Meilan Chen, Duo-Rong Xu, Juan Li, Junru Liu, Zhenhai Zhou, Xiuzhen Tong, Beihui Huang, Lifen Kuang
Publikováno v:
Supportive Care in Cancer
Purpose This randomized, open-label trial was conducted to investigate the optimal duration of bed rest after intrathecal chemotherapy to reduce the incidence of complications without increasing patients’ tolerance to long-term bed rest. Methods A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ad2eb3f567b49d54e3699391381c255
http://europepmc.org/articles/PMC6096529
http://europepmc.org/articles/PMC6096529
Autor:
Xiao-Lu Xu, Huilan Rao, Bing Liao, Juan Li, Hongmei Wu, Xiuzhen Tong, Mei Li, Zhihua Li, Qingqing Cai, Xuanye Zhang
Publikováno v:
Cancer Science
Summary Castleman disease (CD) is a rare lymphoproliferative disorder. To assess the clinical features, outcomes, and prognostic factors of this disease, we retrospectively analyzed 185 HIV-negative CD patients from four medical centers in southern C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51f331acf0c6833294cb03145fd23722
http://europepmc.org/articles/PMC5765290
http://europepmc.org/articles/PMC5765290